<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02147444</url>
  </required_header>
  <id_info>
    <org_study_id>EXPAND study</org_study_id>
    <secondary_id>UMIN000009376</secondary_id>
    <nct_id>NCT02147444</nct_id>
  </id_info>
  <brief_title>Evaluation of Effectiveness and Safety of Xa Inhibitor for the Prevention of Stroke And Systemic Embolism in a Nationwide Cohort of Japanese Patients Diagnosed as Non-valvular Atrial Fibrillation</brief_title>
  <acronym>EXPAND</acronym>
  <official_title>Multi-center, Prospective, Non-interventional, Observational Cohort Study to Investigate Effectiveness and Safety of Rivaroxaban on Prevention of Stroke and Systemic Embolism in Patients With Non-valvular Atrial Fibrillation in Japanese Clinical Practice</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tohoku University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tohoku University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The efficacy and safety of a novel oral Xa inhibitor for stroke and systemic embolism, namely
      rivaroxaban, in non-valvular atrial fibrillation patients are evaluated in Japanese clinical
      practice.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2012</start_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>Combinations of symptomatic stroke (ischemic or hemorrhagic) and systemic embolism</measure>
    <time_frame>up to March/2016</time_frame>
    <description>Primary efficacy endpoint</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinically significant hemorrhagic events (massive hemorrhage in accordance with the ISTH classification)</measure>
    <time_frame>up to March/2016</time_frame>
    <description>Primary safety endpoint</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Combinations of symptomatic stroke (ischemic or hemorrhagic), systemic embolism, myocardial infarction and cardiovascular death</measure>
    <time_frame>up to March/2016</time_frame>
    <description>Secondary efficacy endpoints</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptomatic ischemic stroke</measure>
    <time_frame>up to March/2016</time_frame>
    <description>Secondary efficacy endpoints</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptomatic hemorrhagic stroke</measure>
    <time_frame>up to March/2016</time_frame>
    <description>Secondary efficacy endpoints</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic embolism</measure>
    <time_frame>up to March/2016</time_frame>
    <description>Secondary efficacy endpoints</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute myocardial infarction/unstable angina pectoris</measure>
    <time_frame>up to March/2016</time_frame>
    <description>Secondary efficacy endpoints</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular death</measure>
    <time_frame>up to March/2016</time_frame>
    <description>Secondary efficacy endpoints</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Deep vein thrombosis/pulmonary thromboembolism</measure>
    <time_frame>up to March/2016</time_frame>
    <description>Secondary efficacy endpoints</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transient ischemic attack</measure>
    <time_frame>up to March/2016</time_frame>
    <description>Secondary efficacy endpoints</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interventional/surgical treatment</measure>
    <time_frame>up to March/2016</time_frame>
    <description>Secondary efficacy endpoints</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause death</measure>
    <time_frame>up to March/2016</time_frame>
    <description>Secondary efficacy endpoints</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically insignificant hemorrhagic events (hemorrhagic events other than clinically significant hemorrhagic events)</measure>
    <time_frame>up to March/2016</time_frame>
    <description>Secondary safety endpoint</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">7000</enrollment>
  <condition>Non-valvular Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Non-valvular atrial fibrillation</arm_group_label>
    <description>Patients diagnosed with non-valvular atrial fibrillation
Patients who are treated or will be treated with rivaroxaban</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Non-valvular atrial fibrillation (In the present study, non-valvular atrial fibrillation
        refers to atrial fibrillation without a history of prosthetic valve replacement or mitral
        valve stenosis.)
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients who meet all the criteria below

          -  Patients aged over 20 years

          -  Patients diagnosed with non-valvular atrial fibrillation

          -  Patients who are treated or will be treated with rivaroxaban

          -  Patients from whom written informed consent has been obtained

        Exclusion Criteria:

        Patients who meet any of the criteria below

          -  The following patients in whom rivaroxaban is contraindicated for use

          -  Patients with a history of allergies to the ingredients contained in this drug

          -  Patients having a hemorrhagic event (intracranial hemorrhage, gastrointestinal
             hemorrhage or other clinically significant hemorrhagic events)

          -  Patients having liver disease complicated with coagulation disorder or those having
             moderate or worse liver disorder (Grade B or C in accordance with the Child-Pugh
             classification)

          -  Patients having renal failure (creatinine clearance: &lt;15 mL/min)

          -  Women who are or are likely to be pregnant

          -  Patients who are treated with HIV protease inhibitors (including ritonavir, atazanavir
             and indinavir)

          -  Patients who are treated with oral or injectable formulations of azole antifungal
             drugs (including itraconazole, voriconazole and ketoconazole (excluding fluconazole))
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hiroaki Shimokawa, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Koji Fukuda, M.D., Ph. D</last_name>
    <phone>+81-22-717-7153</phone>
    <email>fukuda@cardio.med.tohoku.ac.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine</name>
      <address>
        <city>Sendai</city>
        <state>Miyagi</state>
        <zip>980-6574</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Koji Fukuda, MD, PhD</last_name>
      <phone>+81-22-717-7153</phone>
      <email>fukuda@cardio.med.tohoku.ac.jp</email>
    </contact>
    <investigator>
      <last_name>Hiroaki Shimokawa, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://cms.captool.jp/expand/</url>
    <description>EXPAND study home page</description>
  </link>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 12, 2014</study_first_submitted>
  <study_first_submitted_qc>May 21, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 26, 2014</study_first_posted>
  <last_update_submitted>May 21, 2014</last_update_submitted>
  <last_update_submitted_qc>May 21, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 26, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tohoku University</investigator_affiliation>
    <investigator_full_name>Hiroaki Shimokawa, MD, PhD</investigator_full_name>
    <investigator_title>MD, PhD, Department of Cardiovascular Medicine</investigator_title>
  </responsible_party>
  <keyword>Rivaroxaban</keyword>
  <keyword>Non-valvular atrial fibrillation</keyword>
  <keyword>NOAC</keyword>
  <keyword>Xa inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Embolism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rivaroxaban</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

